Dimerix Limited · ASX:DXB
Dimerix — 16th Bioshares Biotech Summit 2022
23 slides from Dimerix's conference presentation, May 12, 2022
Slide 1: Dimerix Presents at Bioshares Biotech Summit
Immediate Release DIMERIX PRESENTS AT BIOSHARES BIOTECH SUMMIT MELBOURNE, Australia, 12 May 2022: Dimerix Limited (ASX: DXB), a biopharmaceutical company with Phase 3 clinical studies in inflammatory diseases, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be presenting a
Slide 2: About Dimerix
About Dimerix Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complic
Slide 3: Bioshares Presentation
@ Dimerix (ASX:DXB) Bioshares Presentation 12 May 2022 Authorised for lodgment by the Board of the Company
Slide 4: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 5: Let's begin at the end!
Let’s begin at the end! Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease Multiple late-stage clinical programs in renal and respir
Slide 6: Key achievements during COVID-19
Key achievements during COVID-19 2022 —— > v Completed two Phase 2 renal clinical studies; v Met (virtually) with FDA, EMA and UK MHRA on FSGS Phase 3 study design on several occasions;? v Initiated two independent Phase 8 clinical studies in patients with COVID-19 respiratory complications;3 v Awar
Slide 7: Key mechanisms that cause sclerotic kidney disease
3 key mechanisms that cause sclerotic kidney disease ATIR 1 hyperfiltration of and hypertension within blood vessels of the glomeruli! Dimerix’ proprietary discovery tool determined a functional interaction between AT1R and CCR2? Certain kidney cells express both receptors, thus using only 1 compoun
Slide 8: Renal licensing deals
2,500.00 REG 1x P3 Ren Reg 1x P3 Ren 2,000.00 WW 1x P1 Ren WW 1x P2 Mul 1,500.00 CTRY 1x P3 Ren CTRY 1x P2 Ren 1,000.00 WW 1x P3 Ren Reg 1x Pre Ren 500.00 Reg 1x Pre Ren WW 1x P1 Ren 0.00 Jan-20 Apr-20 Aug-20 Nov-20 Feb-21 Jun-21 Sep-21 Dec-21
Slide 9: Renal licensing deals details - April 2020-2022
Renal licensing deals details - April 2020-2022 (only deals where financials disclosed included) Focal segmental $55.0M Australia, New Zealand, Europe Phase 3 glomerulosclerosis (Primary); IgA Sparsentan nephropathy; Renal disease Sep 2021 Travere Therapeutics Vifor Pharma $845.0M Sep 2021 AM-Pharma
Slide 10: Renal M&A deals
WW Mul WW Mul WW 1x WW 1x WW 1x WW 1x
Slide 11: Renal M&A deals details - April 2020-2022
Renal M&A deals details - April 2020-2022 (only deals where financials disclosed included) Total Deal Date Acquirer Target rin Geography Indications Assets Renal disease (Primary); Albuminuria; Diabetes mellitus; End Jan 2022 Social Capital Suvretta ProKidney $825M _ Worldwide stage renal disease; H
Slide 12: But why now?
But why now?
Slide 13: So what is happening in the renal space?
So what is happening in the renal space? “A squeaky wheel waiting for grease: 50 years of kidney disease management in the US”! Historical lack of incentives and public policy have contributed to high costs and} poor health outcomes for renal patients! 2018: workshops and regulatory acceptance of su
Slide 14: Policy change: renal disease healthcare economic burden
Policy change: renal disease healthcare economic burden “40 million adults have kidney disease (“15% of the adult population) in the US in 20211 2019 White House executive order issued: incentives for providers to delay patient progression to renal failure 2 w Dimerix US$88 billion estimated total U
Slide 15: Clinical study change: use of surrogate endpoints
Clinical study change: use of surrogate endpoints A surrogate endpoint is an intermediate outcome which substitutes the clinically meaningful endpoint Publications demonstrate relationship between FDA publish willingness ae proteinuria as a to consider fixed glomerular filtration rate (GFR) and prot
Slide 16: Perfect timing for DMX-200...
Perfect timing for DMX-200...
Slide 17: Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis * A rare disease\that attacks part of the kidney, causing inflammation and irreversible scarring’; * Leads to permanent kidney damage and eventual end-stage kidney failure, requiring dialysis or transplantation * Dimerix clinical study: encouraging Phase 2 data in
Slide 18: Capital raise structure
Capital raise structure’ * A$20 million institutional and sophisticated investor placement (“Placement”) to fund FSGS program through to 1* Interim Data point * Attaching options (1:2) provide additional “A$24 million’ in proceeds on exercise to fund FSGS program through to Accelerated Approval (on
Slide 19: Accelerated Trigger Event
Accelerated Trigger Event ¢ Accelerated Trigger Event is a specified of event that causes an acceleration of the pre-set vesting or expiry schedule Seen in banks, including ANZ; whereby an accelerated trigger event occurs when common equity capital ratio declines to or below a set % Request less now
Slide 20: FSGS phase 3 study design
FSGS phase 3 study design nt ACTIAN3 FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB ARB stabilisation Treatment period weeks -6 DMX-200 Placebo Randomisation +1 dose * Final analysis (
Slide 21: Ultimately - Dimerix partnering objectives
Ultimately - Dimerix partnering objectives BIO International Convention The Global Byent fot-Biotechnology. OflE PARTNERING™ @ Dimerix BIO-EUROPE’ 1. Outcome that maximizes value 5. Establish competitive tension wherever possible BIOTECH SHOWCASE" [acim partneringONE* 2. Control the entire process 4
Slide 22: Share price / Top shareholders
Share price Top shareholders
Slide 23: Dimerix
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Advancing three Phase 3 opportunities Well positioned to deliver against strategic plan Dimerix HQ